Divaya Bhutani, MD
Hematology · New York, NYNPI 1942404298
Payments from drug & device makers
Across 205 payments — averaging $23,385 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1.2M
- Sanofi US Services Inc.$1.1M
- Janssen Research & Development, LLC$675K
- Sanofi$546K
- Amgen$384K
- Takeda Pharmaceuticals U.S.A., Inc.$377K
- plus $505K from 15 others
What the payments were for
- Consulting fees$12,55583%
- Speaking & faculty fees$4653%
- Travel & lodging$1,1307%
- Food & beverage$1,0357%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 18 | $1,238,479 |
| Sanofi US Services Inc. | 14 | $1,069,401 |
| Janssen Research & Development, LLC | 86 | $675,032 |
| Sanofi | 10 | $545,581 |
| Amgen | 3 | $383,860 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $376,663 |
| Bristol Myers Squibb | 7 | $232,391 |
| Regeneron | 8 | $124,359 |
| E.r. Squibb & Sons, L.L.C. | 7 | $109,204 |
| AbbVie | 4 | $36,344 |
| Johnson & Johnson | 4 | $1,744 |
| Pfizer | 1 | $465 |
| Adaptive Biotechnologies Corporation | 1 | $80 |
| Daiichi Sankyo Inc. | 2 | $53 |
| Karyopharm Therapeutics Inc. | 2 | $48 |
| Recordati_rare_diseases_inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 1 | $34 |
| Incyte Corporation | 2 | $31 |
| Novartis | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Beigene USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,793,877 in reported general payments places this provider in the 95th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 85 | $1,605 |
| Pantoprazole Sodium | 44 | $569 |
| Ondansetron Hcl | 35 | $269 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $84 |
| Furosemide | 14 | $67 |
Paid to pharmacies, not to this prescriber.
Other hematology in New York
- Michael MauroNew York$34.9M
- Adam KittaiNew York$8.2M
- Barry CollerNew York$7.9M
- Ran ReshefNew York$5.4M
- Richard FurmanNew York$3.1M
- Joseph JurcicNew York$1.7M
- Marissa RybsteinNew York$1.6M
- Allyson OceanNew York$1.5M
- Mark HeaneyNew York$1.3M
- Jeffrey ZwickerNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.